Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (313)	10/29/1999 11:22:00 AM
From: StockMiser	Read Replies (1) \| Respond to of 566

LOL...you are right. I trade biotechs based on DD first, Charts second, other trading indications last. My memory is focused mostly on the scientific data. As Seuss himself said, it all comes down to FDA approval, which has nothing to do with charts or short interest. If approved, the shorts will be swept away like tiny row boats in a hurricane. If it fails, the longs will sink with the ship and drown in an ocean of dispair. Neither side will have time to react if they are still holding. All that matters is the data, and the data points to approval. The fact that they have submitted an additional 6 months of data is also to their advantage. The FDA can also look at patients who have recieved continuous treatments for 3 years. I think they have enough to render a decision one way or the other. All of the data I have seen is positive, including the huge response rate. The odds are clearly in favor of approval. My only opinion of "trading factors" is that if we see CLPA on the agenda for the December ODAC, 90% of the shorts will not dare holding until approval, which will alone propell the stock forward. God I love this game :-) SM